Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | BCHE | P06276 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9609808 | 0.84 | SMN1; SMN2 (0.82) | SMN1; SMN2KDM4EPOLBALDH1A1HPGD | |
| SCHEMBL1616690 | 0.81 | MDM2 (0.59) | MDM2BCHEKDM4EL3MBTL1POLB | |
| SCHEMBL3836378 | 0.80 | BCHE (0.64) | MDM2SMN1; SMN2BCHEKDM4EL3MBTL1 | |
| SCHEMBL334709 | 0.80 | CYP17A1 (0.68) | MDM2BCHEKDM4EL3MBTL1POLB | |
| SCHEMBL4174121 | 0.80 | HPGD (0.62) | MDM2SMN1; SMN2BCHEKDM4EL3MBTL1 | |
| SCHEMBL15133569 | 0.79 | MDM2 (0.57) | MDM2SMN1; SMN2BCHEKDM4EL3MBTL1 | |
| SCHEMBL1503994 | 0.79 | MDM2 (0.57) | MDM2SMN1; SMN2BCHEKDM4EL3MBTL1 | |
| SCHEMBL48610 | 0.77 | TSHR (0.69) | MDM2SMN1; SMN2KDM4EL3MBTL1TAAR1 | |
| SCHEMBL282531 | 0.77 | SMN1; SMN2 (0.71) | SMN1; SMN2TAAR1ALDH1A1HPGDGAA | |
| SCHEMBL7251623 | 0.77 | SMN1; SMN2 (0.72) | SMN1; SMN2L3MBTL1POLBALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12268677-B2 | 4-aminopyridine (4-AP) and bone morphogenetic protein 2 (BMP-2) | THE PENN STATE RESEARCH FOUNDATION (US) | 2025-04-08 | — | — | US | claimed |
| US-20230058178-A1 | METHODS AND MATERIALS FOR TREATING NERVE INJURY AND/OR PROMOTING WOUND HEALING | UNITED STATES GOVERNMENT | 2023-02-23 | — | — | US | claimed |
| EP-4093484-A1 | METHODS AND MATERIALS FOR TREATING NERVE INJURY AND/OR PROMOTING WOUND HEALING | THE PENN STATE RESEARCH FOUNDATION (US) | 2022-11-30 | — | — | EP | claimed |
| WO-2021150773-A1 | METHODS AND MATERIALS FOR TREATING NERVE INJURY AND/OR PROMOTING WOUND HEALING | THE PENN STATE RESEARCH FOUNDATION (US) | 2021-07-29 | — | — | WO | claimed |
| CN-103209695-A | Azabenzothiazole compounds, compositions and methods of use | HOFFMANN LA ROCHE | 2013-07-17 | — | — | CN | claimed |
| CN-1169791-C | Novel acetamide derivatives and protease inhibitors | �ձ���ҩ��ʽ���� | 2004-10-06 | — | — | CN | claimed |
| CN-1341590-A | Proteinase inhibitor | SMITHKLINE BEECHEM CORP (US) | 2002-03-27 | — | — | CN | claimed |
| CN-1229405-A | Novel acetamide derivatives and protease inhibitors | NIPPON KAYAKU KK (JP) | 1999-09-22 | — | — | CN | claimed |
| CN-1207095-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 1999-02-03 | — | — | CN | claimed |
| EP-4648773-A1 | POTASSIUM CHANNEL BLOCKERS OR DERIVATIVES THEREOF FOR PREVENTING, ALLEVIATING, AND/OR TREATING MORBIDITY AND MORTALITY INDUCED BY PATHOGENS OR OTHER INDUCERS OF IMMUNE EXHAUSTION AND/OR EXCESS IMMUNE ACTIVATION | University of Rochester (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20250228830-A1 | 4-AMINOPYRIDINE (4-AP) AND BONE MORPHOGENETIC PROTEIN 2 (BMP-2) | THE PENN STATE RESEARCH FOUNDATION | 2025-07-17 | — | — | US | disclosed |
| EP-4551217-A1 | POTASSIUM CHANNEL BLOCKERS OR DERIVATIVES THEREOF FOR PREVENTING, ALLEVIATING, AND/OR TREATING TISSUE DYSFUNCTION CAUSED BY TOXIC INSULTS | University of Rochester (US) | 2025-05-14 | — | — | EP | disclosed |
| US-12268677-B2 | 4-aminopyridine (4-AP) and bone morphogenetic protein 2 (BMP-2) | THE PENN STATE RESEARCH FOUNDATION (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240309019-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-09-19 | — | — | US | disclosed |
| WO-2004052291-A2 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | PURDUE RESEARCH FOUNDATION (US) | 2004-06-24 | — | — | WO | disclosed |
| CN-1341593-A | Proteinase inhibitor | SMITHKLINE BEECHEM CORP (US) | 2002-03-27 | — | — | CN | disclosed |
| CN-1341590-A | Proteinase inhibitor | SMITHKLINE BEECHEM CORP (US) | 2002-03-27 | — | — | CN | disclosed |
| CN-1341592-A | Proteinase inhibitor | SMITHKLINE BEECHEM CORP (US) | 2002-03-27 | — | — | CN | disclosed |
| CN-1229405-A | Novel acetamide derivatives and protease inhibitors | NIPPON KAYAKU KK (JP) | 1999-09-22 | — | — | CN | disclosed |
| CN-1207095-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 1999-02-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250228830-A1 | 4-AMINOPYRIDINE (4-AP) AND BONE MORPHOGENETIC PROTEIN 2 (BMP-2) | BMP4, BMP2, BMP1 | MDM2 1392/4885SMN1; SMN2 2110/4885BCHE 2007/4885 |
| US-12268677-B2 | 4-aminopyridine (4-AP) and bone morphogenetic protein 2 (BMP-2) | BMP4, BMP2, BMP1 | MDM2 1392/4885SMN1; SMN2 2110/4885BCHE 2007/4885 |
| US-20240309019-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | F2RL3, PARP14, F2R | MDM2 1932/4885SMN1; SMN2 4221/4885BCHE 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.